Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.

Biomed Pharmacother. 1999 Mar;53(2):90-2. Unique Identifier : AIDSLINE MED/99269757
Zagury D; Lecoq H; Gervi I; Le Buanec H; Zagury JF; Bizzini B; Burny A; Hermans P; Perja M; Santagostino E; Gringeri A; Laboratoire de Physiologie Cellulaire, P. et M. Curie University,; Paris, France.

Abstract: HAART (highly active antiretroviral therapy) suppresses but does not eradicate HIV-1 infection. However, since the antiretroviral agents used in HAART may also be toxic in the long-term, immunotherapies which correct HIV-1 immunosuppression or the cytokine dysregulation associated with it may be beneficial. In this respect, a double blind multicentric placebo-controlled phase II/III anti-IFN alpha vaccine trial has been carried out on 242 HIV-1 patients, the majority of whom were undergoing HAART treatment. In vaccinated patients (vaccinees) who responded to immunization by increased levels of IFN alpha Abs (whether under HAART or not) when compared to placebo or non-responder vaccinees, a strong correlation was found between an increased IFN alpha neutralizing capacity and the reduction of clinical manifestations.

Keywords: CLINICAL TRIAL CLINICAL TRIAL, PHASE II CLINICAL TRIAL, PHASE III JOURNAL ARTICLE MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL Anti-HIV Agents/*THERAPEUTIC USE Autoantibodies/*IMMUNOLOGY AIDS Vaccines/THERAPEUTIC USE Chemotherapy, Adjuvant Double-Blind Method Human HIV Infections/PHYSIOPATHOLOGY/*THERAPY *Immunization Interferon Alfa-2b/*IMMUNOLOGY Vaccines/*THERAPEUTIC USE
990930
A9991289

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .